Phosphodiesterase type 5 inhibitors for lower urinary tract symptoms induced by benign prostatic hyperplasia: an update.
- Author:
Peng-Bin HE
;
Pei-Jin ZHA
;
Dong-Ping XU
- Publication Type:Journal Article
- MeSH:
Humans;
Lower Urinary Tract Symptoms;
drug therapy;
etiology;
Male;
Phosphodiesterase 5 Inhibitors;
therapeutic use;
Prostatic Hyperplasia;
complications
- From:
National Journal of Andrology
2014;20(7):651-656
- CountryChina
- Language:Chinese
-
Abstract:
Medication has become the first-line option for the management of lower urinary tract symptoms induced by benign prostatic hyperplasia (LUTS/BPH) for its advantages in controlling the symptoms, inhibiting BPH progression, and reducing serious complications and surgical risks. Recent years have witnessed remarkable achievement in the studies of phosphodiesterase type 5 inhibitors (PDE5-Is) in the treatment of LUTS/BPH. PDE5-Is can effectively alleviate LUTS/BPH, with even better efficacy when combined with al-ARAs.
